A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community‐based testing campaign

2021 ◽  
Author(s):  
Anna Y Palmer ◽  
Kico Chan ◽  
Judy Gold ◽  
Chloe Layton ◽  
Imogen Elsum ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Financial Incentives ◽  
Community Based ◽  
Treatment Uptake ◽  
Modelling Analysis

scholarly journals Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Stelliana Goutzamanis ◽  
Danielle Horyniak ◽  
Joseph S. Doyle ◽  
Margaret Hellard ◽  
Peter Higgs ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Physical Health ◽  
Antiviral Treatment ◽  
Health Benefits ◽  
Community Treatment ◽  
Physical And Mental Health ◽  
Structured Interviews ◽  
Direct Acting Antiviral ◽  
Treatment Uptake ◽  
Direct Acting

Abstract Background Novel health promotion and treatment uptake initiatives will be necessary to ensure Australia meets 2030 hepatitis C elimination targets. Increasing treatment uptake will be assisted by a better understanding of the treatment experience and patient-perceived benefits. This study describes the perceived physical health benefits from direct-acting antiviral (DAA) hepatitis C treatment among people who inject drugs in Melbourne, Australia. Methods Twenty participants were recruited from a community treatment trial and community health clinics. Semi-structured interviews were performed with each participant before, during and following treatment. Interviews focused on treatment experiences, attitudes and motivations. Interviews were recorded, transcribed and thematically analysed. Results Two themes relating to the physical experience of treatment developed; intersection between physical and mental health and “maybe it’s working”. Participants reported various physical benefits, most prominently, reduced fatigue. Reductions in fatigue resulted in instant and meaningful changes in everyday life. Some participants did experience side effects, which they described as mild. Experiencing noticeable physical benefits during treatment was perceived as validation that treatment was working. Conclusion Physical health benefits of DAA treatment may have carry-on effects on cognitive, emotional or social wellbeing and should be incorporated into how treatment is promoted to those who require it.

Incident hepatitis C virus infection in a community-based population in Japan

2002 ◽  
Vol 9 (1) ◽  
pp. 43-51 ◽  
Author(s):  
A. Okayama ◽  
S. O. Stuver ◽  
E. Tabor ◽  
N. Tachibana ◽  
M. Kohara ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Hepatitis C Virus Infection ◽  
Community Based

scholarly journals Outcomes of the CT2 Study: A ‘one‐stop‐shop’ for community‐based hepatitis C testing and treatment in Yangon, Myanmar

2021 ◽  
Author(s):  
Bridget Draper ◽  
Hla Htay ◽  
Alisa Pedrana ◽  
Win Lei Yee ◽  
Jessica Howell ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Community Based ◽  
One Stop

scholarly journals The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0247843
Author(s):  
Harriet Ho ◽  
Naveed Z. Janjua ◽  
Kimberlyn M. McGrail ◽  
Mark Harrison ◽  
Michael R. Law ◽  
...  
Keyword(s):  
British Columbia ◽  
Hepatitis C ◽  
Private Insurance ◽  
Insurance Coverage ◽  
Drug Coverage ◽  
Administrative Claims ◽  
Public And Private ◽  
Treatment Uptake ◽  
Private Expenditure ◽  
The Impact

Background Sofosbuvir and ledipasvir-sofosbuvir are both newer direct-acting antiviral agents for the treatment of hepatitis C. The high list prices for both drugs have led to concern about the budget impact for public drug coverage programs. Therefore, we studied the impact of public prescription drug coverage for both drugs on utilization, adherence, and public and private expenditure in British Columbia, Canada. Methods We used provincial administrative claims data from January 2014 to June 2017 for all individuals historically tested for either hepatitis C and/or human immunodeficiency virus. Using interrupted time series analysis, we examined the impact of public insurance coverage on treatment uptake, adherence (proportion of days covered), and public and private expenditures. Results Over our study period, 4,462 treatment initiations were eligible for analysis (1,131 sofosbuvir and 3,331 ledipasvir-sofosbuvir, which include 19 patients initiated on both treatments). We found the start of public coverage for sofosbuvir and ledipasvir-sofosbuvir increased treatment uptake by 154%. Adherence rates were consistently high and did not change with public coverage. Finally, public expenditure increased after the policy change, and crowded out some private expenditure. Conclusion Public coverage for high-cost drugs for hepatitis C dramatically increased use of these drugs, but did not reduce adherence. From a health policy perspective, public payers should be prepared for increased treatment uptake following the availability of public coverage. However, they should not be concerned that populations without private insurance coverage will be less adherent and not finish their treatment course.

Sign in / Sign up

Export Citation Format

Share Document